Phosphodiesterase Inhibitors
1 drugsAbout Phosphodiesterase
Phosphodiesterases (PDEs) are enzymes that regulate intracellular signaling by hydrolyzing phosphodiester bonds in cyclic nucleotides like cAMP and cGMP. These cyclic nucleotides act as second messengers, and PDEs control the duration and intensity of cellular responses. PDEs are attractive targets for drug development due to their involvement in key signaling pathways.
Currently, there is no genetic evidence available linking phosphodiesterases to specific diseases. However, the established role of PDEs in regulating key cellular functions suggests that modulating their activity could have therapeutic benefits.
There is one FDA-approved drug, ASPIRIN AND DIPYRIDAMOLE, that targets phosphodiesterases. This drug, approved in 2009, is a small molecule used in the cardiovascular therapeutic area.
Top Phosphodiesterase Drugs
AMNEAL PHARMS is the only company with an approved drug targeting phosphodiesterases.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's druggability.
Phosphodiesterase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Phosphodiesterase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer a competitive advantage.
Phosphodiesterase Clinical Trials 531 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Phosphodiesterase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 72 | 57 | 3 | 10 | 95% |
| Phase 2 | 107 | 68 | 17 | 21 | 80% |
| Phase 3 | 128 | 54 | 22 | 52 | 71% |
| Phase 4 | 224 | 125 | 29 | 70 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phosphodiesterase Drug Approval Timeline (2009 - 2009)
The first and only drug, ASPIRIN AND DIPYRIDAMOLE, was approved in 2009.
The lack of recent approvals suggests potential saturation or challenges in developing new PDE-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 328 (49 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Phosphodiesterase. A trial counts if an approved drug acting on Phosphodiesterase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.